^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SLC34A2-ROS1 fusion

    i
    Other names: SLC34A2, Solute carrier family 34 member 2, Type II sodium-dependent phosphate transporter 3b, Sodium-phosphate transport protein 2B, NAPI-3B, NaPi-2b, ROS1, ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyros
    Entrez ID:
    6098; 10568
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    CD74/SLC34A2-ROS1 fusion variants involving the transmembrane region predict poor response to crizotinib in non-small cell lung cancer independent of TP53 mutations. (PubMed, J Thorac Oncol)
    Long CD74/SLC34A2-ROS1 fusions, which retain transmembrane regions in ROS1 and fusion partners, are associated with poor response to crizotinib independent of TP53 mutations.
    Journal
    |
    TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD74 (CD74 Molecule) • SLC34A2 (Solute carrier family 34 member 2) • TPM3 (Tropomyosin 3) • SDC4 (Syndecan 4)
    |
    TP53 mutation • ROS1 fusion • ROS1 rearrangement • SDC4-ROS1 fusion • BCL2L11 deletion • SLC34A2-ROS1 fusion
    |
    Xalkori (crizotinib)